Category Archives: Terapiområde

Sixera Pharma AB

 CEO: Maarten de Chateausixera_

Web: N/A

Description: Sixera Pharma is a biopharmaceutical company with expertise in dermatology, and especially rare genetic skin diseases (genodermatoses). We are focusing our drug development effort on protease biology in the skin and have developed a series of compounds targeting certain skin proteases (kallikreins) known to cause a rare inherited skin disease called Netherton’s syndrome. The lead compound is currently undergoing IND enabling studies.

Janssen

CEO Janssen, Nordic:  Lars Johanssonjanssen_

Web: www.janssen.com/sweden  and www.janssen.com

About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us on www.twitter.com/janssenEMEA for our latest news.

Promore Pharma AB

CEO: Jonas Ekblompromorepharma

Web: www.promorepharma.com

About Promore Pharma AB
Promore Pharma is a small biopharmaceutical company specialized in the development of therapeutic peptides for local application in wounds and skin infections. The company’s vision is to develop a portfolio of unique first-in-class products in the field of advanced wound care. The current development pipeline includes several therapeutic peptides in clinical development, with potential for use in several medical applications. Please visit our web site: www.promorepharma.com.

Biosergen AS

CEO: Anders KronströmBiosergen AS

Web: www.biosergen.se

Description: Biosergen AS is a biotech company developing new drugs based on cutting edge biosynthetic engineering of natural products, combined with chemical synthesis. Established in 2004, the company is based in Trondheim, Norway and focuses its innovative research on fighting systemic fungal infections. Biosergen’s lead compound, BSG005, is currently in pre-clinical development phase.

The company is currently focusing on delivering a proof-of-concept program for BSG005 as well as on seeking partners for out-licensing and the continued development of BSG005.

The current major owners of Biosergen are Karolinska Development AB, Rosetta Capital, Östersjöstiftelsen, and Sintef Venture II.

Sobi

CEO:  Geoffrey McDonoughsobi2012

Web: www.sobi.com

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.